1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > BUSINESS
BUSINESS
- GSK’s Pediatric Antibiotic Clavamox to Be Out of Stock on Demand Spike
May 25, 2023
- Some 400 General Employees Likely Leaving Bayer under Redundancy Program
May 25, 2023
- Lilly’s Omvoh Launch Set for June 21; BioMarin’s Palynziq Now Available
May 25, 2023
- Novartis Japan Rolling Out New Operational Model Tailored to Local Needs: President
May 24, 2023
- Mitsubishi Tanabe to Refine Growth Scenario, Expand Overseas Operations under New Leadership
May 24, 2023
- Oncodesign, Veritas Form Collab for mRNA Drug Development
May 24, 2023
- Lecanemab Filed in UK, Designated under Innovative Pathway: Eisai/Biogen
May 23, 2023
- Sawai and Towa Profits Tank 50% on Flat Sales in Japan: FY2022 Earnings
May 22, 2023
- Astellas CEO Confident about Veozah Uptake, 500 Billion Yen Sales Potential
May 22, 2023
- Mounjaro No. 1 in GP Promotion in March, Dayvigo Most Detailed for HPs
May 22, 2023
- Nipro’s Nexium AG Grabs 53% Market Share in Just 4 Months
May 22, 2023
- Daiichi Sankyo Begins Japan PIII for Omicron-Tailored Jab
May 22, 2023
- Top 4 Wholesalers on Solid Note with 30% Operating Profit Rise in FY2022
May 19, 2023
- Taiho Seals Trial Pact for Arcus Oncology Meds to Work with Gilead
May 19, 2023
- Qol to Further Expand Espha's AG Biz, Eyes Biosame Territory: Exec
May 19, 2023
- BMS Files Luspatercept for MDS Associated Anemia in Japan
May 19, 2023
- Lecanemab’s Social Value in Japan Simulated at 4.7 Million Yen per Patient/Year: Eisai
May 18, 2023
- Xocova Makes Up 11% of COVID Oral Drug Prescriptions Filled Outside Pharmacies
May 18, 2023
- Santen Set to Thwart Post-Launch Challenges Expected for Myopia Drug Hopefuls: President
May 18, 2023
- Takeda’s cTTP Therapy Gets Priority Review in US
May 18, 2023
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…